European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season Merck & Co.—known as MSD outside the United States and Canada—has announced a major regulatory…
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management At the ESCMID Global 2026, Bruker Corporation unveiled a wide-ranging set of portfolio enhancements spanning microbial identification, outbreak surveillance, and reflex next-generation sequencing (NGS) workflows. These updates…
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home…
Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the U.S. launch of Sdamlo™ (amlodipine for…
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Yvonne McGrath,…
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of its concurrent public…
Imperative Care Initiates ADAPT 2.0 Study Evaluating Advanced Clinical Technique Designed to Simplify Acute Ischemic Stroke Treatment Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced that initial patients have been…
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of…
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors Orum Therapeutics, a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Maria Koehler, M.D., Ph.D., and Geoff Meyerson to its Board…
U.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC Patients After Platinum Therapy Daiichi Sankyo and Merck & Co. have reached an important regulatory milestone with the U.S. Food and Drug Administration accepting their Biologics License Application (BLA)…
Prothena Corporation plc Reports Updates to Its Leadership Team Prothena Corporation plc (NASDAQ: PRTA), a late-stage biotechnology company focused on developing therapies for diseases driven by protein dysregulation, has announced a series of leadership updates aimed at strengthening its executive…
Byondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Strengthening Leadership with Multimedia Announcement Byondis B.V., an independent biotechnology company focused on the development of innovative targeted therapies for cancer, has announced a significant leadership transition with the appointment…